Insys Therapeutics Reports Fourth Quarter and Year End 2015 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- US stock futures rise as oil pullback amplifies Fed rate-hike boost
- Oil falls 3% to one-week low as supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- Exclusive-SK Hynix in talks with Intel about deal to make memory chips in US for the first time, sources say
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Turkish Stocks Fall 6%, Triggering Market-wide Circuit Breaker - Bloomberg
Piper Jaffray Cuts Price Target as Insys Therapeutics' (INSY) Guides to a Decline in Subsys Sales
February 24, 2016 10:20 AM ESTPiper Jaffray maintained an Overweight rating on INSYS Therapeutics (NASDAQ: INSY), and cut the price target to $46.00 (from $49.00), following the company's 4Q earnings report. Insys reported adjusted diluted EPS of $0.36 on revenues of $91M, in-line with Street estimates. INSY is guiding to a sequential decline in Subsys sales in 1Q16, driven in significant part by the company no longer contracting with OptumRx. This is... More
Insys Therapeutics (INSY) Tops Q4 EPS by 7c
February 23, 2016 6:50 AM ESTInsys Therapeutics (NASDAQ: INSY) reported Q4 EPS of $0.36, $0.07 better than the analyst estimate of $0.29. Revenue for the quarter came in at $91.1 million versus the consensus estimate of $91.04 million.
For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.
... More